The molecular
innovation engine
of AXIONOVA™.
ARCHE designs peptides, proteins, and pharmaceutical assets from first principles for longevity-relevant biology. ARC-001 is its first engineered molecule, the beginning of the portfolio, not the endpoint.
Hi, I am ALETHA. I help you understand your data and prepare it for your practitioner. I do not make clinical decisions; your practitioner does.
ALETHRA™ governs; ALETHA™ guides. Governing ARCHE
Compounds engineered
for defined biology.
Not repackaged.
ARCHE is AXIONOVA™’s de novo molecular engineering division. It designs custom peptides, proteins, and pharmaceutical assets for longevity-relevant pathways, then connects each candidate to ALETHA™ interpretation and ALETHRA™ governance. It is not a retail supplement brand, a public product catalog, or a speculative availability page.
Design from first principles.
Advance only through evidence gates.
ARCHE designs molecular candidates against a defined biological objective, ranks analogs on structure and pathway fit, and advances each candidate only through governed evidence gates. ARC-001 is the first molecule to clear that pipeline.
The first engineered
molecule from ARCHE.
ARC-001 is a 32-residue cyclic, stapled, cell-penetrating longevity peptide engineered for dual-pathway engagement. It establishes the division’s proof of philosophy: a molecule built from first principles, protected within the AXIONOVA™ technology portfolio, and studied inside a governed research framework. It is described here for research and access-qualification context, not as a claim of clinical benefit.
Advanced Formulation Science: AXIONOVA™ ARCHE represents proprietary molecular engineering capabilities. Information on this page is provided for scientific and educational context. All clinical applications of ARCHE-developed compounds require physician prescription and are dispensed through licensed compounding pharmacies. AXIONOVA™ does not practice medicine.
Innovation does not pause.
Access is not open. AXIONOVA™ ARCHE requires registration and qualification review.